[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438243":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":32,"collaborators":7,"id":34,"slug":7,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":7,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":51,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},{"fullName":5,"class":6},"National Cancer Centre, Singapore","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Valerie Shiwen Yang, BSc, MB BChir, PhD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+65 6436 8088","valerie.yang.s.w@singhealth.com.sg",[18],{"facility":19,"status":20,"city":21,"state":7,"zip":22,"country":21,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"National Cancer Centre Singapore","RECRUITING","Singapore","169610","SG",{"type":25,"coordinates":26},"Point",[27,28],103.85007,1.28967,{"lat":28,"lon":27},[31],{"name":10,"role":14,"phone":7,"phoneExt":7,"email":7},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100438243",false,"NCT04986748","Using QPOP to Predict Treatment for Sarcomas and Melanomas","Q-SAM (Using QPOP to Predict Treatment for Sarcomas and Melanomas)","Inclusion Criteria:\n\n* Diagnosis of sarcoma or melanoma\n* At least 1 tumour lesion amenable to fresh biopsy or resection\n* Signed informed consent from patient or legal representative\n* Able to comply with study-related procedures\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria if patients meet the inclusion criteria","ALL","21 Years","99 Years",{"count":44,"type":45},100,"ESTIMATED","OBSERVATIONAL","This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.\n\nEnrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.",[49,50],"Sarcoma","Melanoma",[52,53,54,55,56],"Tumour-derived models","Organoids","Ex vivo drug testing","Personalised therapy","QPOP","2025-06-29",{"date":59,"type":60},"2025-07-01","ACTUAL",{"date":62,"type":60},"2020-09-08",{"date":64,"type":45},"2028-12-31",{"name":5,"class":6},1]